SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act 1934
Date of Report: October 15, 1997
INTERNEURON PHARMACEUTICALS, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
DELAWARE
- --------------------------------------------------------------------------------
(State of other jurisdiction of incorporation)
0-18728 043047911
- ------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
One Ledgemont Center, 99 Hayden Avenue, Lexington, Massachusetts 02173
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone no. including area code: (617) 861-8444
--------------
ITEM 5. OTHER EVENTS
------------
Interneuron Pharmaceuticals, Inc. (the "Company") has been named as a
defendant in a lawsuit filed in the United States District Court for the
District of Massachusetts by an alleged purchaser of the Company's common stock.
The plaintiff, Peter Cusmano, claims to have purchased 250 shares of the
Company's Common Stock on July 16, 1997 and another 150 shares on August 28,
1997. The purported class action complaint alleges, among other things, that the
Company publicly disseminated materially false and misleading statements
concerning the prospects and safety of Redux(TM), resulting in the artificial
inflation of the Company's common stock price during the period of March 1, 1997
through September 12, 1997, in violation of the federal securities laws. The
complaint,which also names as defendants certain of the Company's officers and
directors, seeks unspecified monetary damages on behalf of purchasers of the
Company's common stock during the specified period. The Company believes it has
meritorious defenses and intends to vigorously defend against this and any
similar future lawsuits.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERNEURON PHARMACEUTICALS INC.
By: /s/ Glenn L. Cooper
-----------------------------
Glenn L. Cooper, M.D.
President and Chief Executive Officer
Dated: October 15, 1997
-3-
